-
Something wrong with this record ?
Cannabis-derived products antagonize platinum drugs by altered cellular transport
T. Buchtova, L. Beresova, K. Chroma, T. Pluhacek, T. Beres, D. Kaczorova, P. Tarkowski, J. Bartek, M. Mistrik
Language English Country France
Document type Journal Article
- MeSH
- Cannabinoid Receptor Agonists MeSH
- Analgesics MeSH
- Cannabis * MeSH
- Hallucinogens * MeSH
- Cannabidiol * pharmacology therapeutic use MeSH
- Cannabinoids * therapeutic use MeSH
- Pharmaceutical Preparations MeSH
- Humans MeSH
- Platinum MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
Cannabinoids, a class of compounds derived from Cannabis sativa L., have recently become more widely accessible for public consumption in the form of diverse cannabis products, in parallel with weakening the measures that so far restricted their availability. The US Food and Drug Administration has approved several cannabis-derived drugs for management of various diseases as well as chemotherapy-induced nausea and vomiting. Besides the attenuation of adverse effects of chemotherapy, numerous reports about cannabinoid-mediated anticancer effects further motivate cancer patients to support their therapy with such products. Here we present a set of preclinical data with human cell culture models, suggesting that cannabidiol and cannabis extracts may effectively counteract the anticancer effects of the clinically widely used standard-of-care platinum-based drugs. We show that even low concentrations of cannabinoids reduced the toxicity of cisplatin, oxaliplatin, and carboplatin, an effect which was accompanied by decreased platinum adduct formation and a set of commonly used molecular markers. Mechanistically, our results excluded the possibility that the observed enhanced survival of cancer cells was mediated transcriptionally. Instead, trace metal analyses strongly indicate an inhibitory impact of cannabinoids on intracellular platinum accumulation, thereby implicating changes in cellular transport and/or retention of these drugs as the likely cause of the observed biological effects. Our study raises the possibility that the desirable effect of counteracting adverse effects of chemotherapy might, at least for some cannabinoids, reflect impaired cellular availability, and consequently attenuation of the anticancer effects of platinum drugs. DATA AVAILABILITY: All data supporting the conclusions are available in the article and supplementary files. Raw data are available upon request from the corresponding author.
Czech Advanced Technology and Research Institute Palacký University Olomouc Czech Republic
Danish Cancer Society Research Center DK 2100 Copenhagen Denmark
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23010907
- 003
- CZ-PrNML
- 005
- 20250506100749.0
- 007
- ta
- 008
- 230718e20230501fr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.biopha.2023.114801 $2 doi
- 035 __
- $a (PubMed)37137184
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a fr
- 100 1_
- $a Buchtova, Tereza $u Faculty of Medicine and Dentistry, Institute of Molecular and Translational Medicine, Palacký University, Olomouc, Czech Republic
- 245 10
- $a Cannabis-derived products antagonize platinum drugs by altered cellular transport / $c T. Buchtova, L. Beresova, K. Chroma, T. Pluhacek, T. Beres, D. Kaczorova, P. Tarkowski, J. Bartek, M. Mistrik
- 520 9_
- $a Cannabinoids, a class of compounds derived from Cannabis sativa L., have recently become more widely accessible for public consumption in the form of diverse cannabis products, in parallel with weakening the measures that so far restricted their availability. The US Food and Drug Administration has approved several cannabis-derived drugs for management of various diseases as well as chemotherapy-induced nausea and vomiting. Besides the attenuation of adverse effects of chemotherapy, numerous reports about cannabinoid-mediated anticancer effects further motivate cancer patients to support their therapy with such products. Here we present a set of preclinical data with human cell culture models, suggesting that cannabidiol and cannabis extracts may effectively counteract the anticancer effects of the clinically widely used standard-of-care platinum-based drugs. We show that even low concentrations of cannabinoids reduced the toxicity of cisplatin, oxaliplatin, and carboplatin, an effect which was accompanied by decreased platinum adduct formation and a set of commonly used molecular markers. Mechanistically, our results excluded the possibility that the observed enhanced survival of cancer cells was mediated transcriptionally. Instead, trace metal analyses strongly indicate an inhibitory impact of cannabinoids on intracellular platinum accumulation, thereby implicating changes in cellular transport and/or retention of these drugs as the likely cause of the observed biological effects. Our study raises the possibility that the desirable effect of counteracting adverse effects of chemotherapy might, at least for some cannabinoids, reflect impaired cellular availability, and consequently attenuation of the anticancer effects of platinum drugs. DATA AVAILABILITY: All data supporting the conclusions are available in the article and supplementary files. Raw data are available upon request from the corresponding author.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a Cannabis $7 D002188
- 650 _2
- $a léčivé přípravky $7 D004364
- 650 _2
- $a platina $7 D010984
- 650 12
- $a kanabinoidy $x terapeutické užití $7 D002186
- 650 12
- $a kanabidiol $x farmakologie $x terapeutické užití $7 D002185
- 650 12
- $a halucinogeny $7 D006213
- 650 _2
- $a agonisté kanabinoidních receptorů $7 D063386
- 650 _2
- $a analgetika $7 D000700
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Béresová, Lucie $u Faculty of Medicine and Dentistry, Institute of Molecular and Translational Medicine, Palacký University, Olomouc, Czech Republic $7 xx0329564
- 700 1_
- $a Chroma, Katarina $u Faculty of Medicine and Dentistry, Institute of Molecular and Translational Medicine, Palacký University, Olomouc, Czech Republic
- 700 1_
- $a Pluhacek, Tomas $u Department of Analytical Chemistry, Faculty of Science, Palacký University Olomouc, 17. listopadu 12, 771 46 Olomouc, Czech Republic
- 700 1_
- $a Beres, Tibor $u Czech Advanced Technology and Research Institute, Palacký University, Olomouc, Czech Republic
- 700 1_
- $a Kaczorova, Dominika $u Czech Advanced Technology and Research Institute, Palacký University, Olomouc, Czech Republic; Centre of the Region Haná for Biotechnological and Agricultural Research, Department of Genetic Resources for Vegetables, Medicinal and Special Plants, Crop Research Institute, Olomouc, Czech Republic
- 700 1_
- $a Tarkowski, Petr $u Czech Advanced Technology and Research Institute, Palacký University, Olomouc, Czech Republic; Centre of the Region Haná for Biotechnological and Agricultural Research, Department of Genetic Resources for Vegetables, Medicinal and Special Plants, Crop Research Institute, Olomouc, Czech Republic
- 700 1_
- $a Bártek, Jiří, $d 1953- $u Danish Cancer Society Research Center, DK-2100 Copenhagen, Denmark; Division of Genome Biology, Department of Medical Biochemistry and Biophysics, Science for Life Laboratory, Karolinska Institute, 171 77 Stockholm, Sweden $7 xx0046271
- 700 1_
- $a Mistrik, Martin $u Faculty of Medicine and Dentistry, Institute of Molecular and Translational Medicine, Palacký University, Olomouc, Czech Republic. Electronic address: martin.mistrik@upol.cz
- 773 0_
- $w MED00005486 $t Biomedicine & pharmacotherapy $x 1950-6007 $g Roč. 163 (20230501), s. 114801
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37137184 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230718 $b ABA008
- 991 __
- $a 20250506100748 $b ABA008
- 999 __
- $a ok $b bmc $g 1963367 $s 1197172
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 163 $c - $d 114801 $e 20230501 $i 1950-6007 $m Biomedicine & pharmacotherapy $n Biomed Pharmacother $x MED00005486
- LZP __
- $a Pubmed-20230718